0001626199-23-000145.txt : 20231221
0001626199-23-000145.hdr.sgml : 20231221
20231221193553
ACCESSION NUMBER: 0001626199-23-000145
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231219
FILED AS OF DATE: 20231221
DATE AS OF CHANGE: 20231221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rickey James Paul
CENTRAL INDEX KEY: 0001606243
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 231506843
MAIL ADDRESS:
STREET 1: ALPINE IMMUNE SCIENCES, INC.
STREET 2: 188 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wk-form4_1703205343.xml
FORM 4
X0508
4
2023-12-19
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001606243
Rickey James Paul
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
0
1
0
0
See Remarks
1
Common Stock
2023-12-19
4
M
0
15213
5.02
A
15213
D
Common Stock
2023-12-19
4
S
0
15213
19.2087
D
0
D
Stock Option (Right to buy)
5.02
2023-12-19
4
M
0
15213
0
D
2027-04-11
Common Stock
15213
535
D
The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023.
This transaction was executed in multiple trades at prices ranging from $19.01 to $19.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
100% of the shares underlying the option were fully vested as of April 1, 2021.
Senior Vice President, Chief Financial Officer and Corporate Secretary
/s/ James Paul Rickey
2023-12-21